Table 3 Exosomal circRNAs as cancer biomarkers
From: Exosomal circRNA: emerging insights into cancer progression and clinical application potential
Exosomal circRNA | Type of disease | Source of exosome | Expression | Clinical relevance | Case number | AUC | Sensitivity and specificity | References |
|---|---|---|---|---|---|---|---|---|
circPDLIM5, etc. | Prostate cancer | Urine | ↑ | _ | 263 in training cohort; 497 in validation cohort 1; 505 in validation cohort 2 | 0.820 in training cohort; 0.807 in validation cohort 1; 0.810 in validation cohort 2 | _ | [145] |
circ_0047921, circ_0056285, circ_0007761 | Non-small cell lung cancer | Serum | ↓ ↓ ↑ | circ_0056285: clinical stages and lymph node metastasis | 120 in training set; 62 in validation set1; 63 in validation set2 | Combined:0.926 in training set;0.919 in validation set | _ | [153] |
circ_0070396 | Hepatocellular cancer | Plasma | ↑ | AFP, AST, ALT, ALB, TBIL, DBIL | 111 | 0.8574 | Sensitivity:62.16% Specificity:98.15% | [154] |
hsa_circ_0001439, hsa_circ_0001492, hsa_circ_0000896 | Lung adenocarcinoma | Serum | ↑ ↑ ↑ | TNM stage, tumor size, NSE, CEA | 134 | Combined:0.805 | Sensitivity:73.2%; 66.1%;62.2% Specificity:70.8%;84%;87.5% | [155] |
hsa_circ_0055202, hsa_circ_0074920, hsa_circ_0043722 | Glioblastoma multiforme | Plasma | ↑ ↑ ↑ | _ | 120 | Combined:0.988 in training set; 0.925 in validation set | _ | [156] |
circMYC | Radio-resistant nasopharyngeal carcinoma | Serum | ↑ | Tumor size, lymph node metastasis, TNM stage, survival rate, and disease recurrence | 210 | 0.945 | _ | [157] |
BCExoC (hsa_circ_0002190, etc.) | Breast cancer | Plasma | ↑ | _ | 144 in training cohort; 101 in testing cohort; | SVM:0.83 in training cohort; 0.80 in testing cohort | _ | [158] |